Shopping Cart
- Remove All
- Your shopping cart is currently empty
JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $137 | 1-2 weeks | |
5 mg | $617 | 1-2 weeks | |
10 mg | $995 | 1-2 weeks | |
25 mg | Inquiry | 1-2 weeks | |
50 mg | Inquiry | 1-2 weeks |
Description | JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma. |
In vitro | In MM.1S and MOLP-8 cells, JQKD82 (1 μM) induces G1 cell cycle arrest. JQKD82 (0.3 μM) increases global H3K4me3 levels in MM.1S cells. JQKD82 (0.1-10 μM) inhibits the growth of MM.1S cells in a dose- and time-dependent manner (IC50 = 0.42 μM)[1]. |
In vivo | In female NSG mice bearing MOLP-8 TurboGFP-Luc cells, JQKD82 (50 and 75 mg/kg; i.p.) significantly reduces tumor burden. JQKD82 increases the level of H3K4me3 and significantly reduces MYC immuno-staining in vivo[1]. |
Alias | PCK82, JQKD82, JADA82 |
Molecular Weight | 500.63 |
Formula | C27H40N4O5 |
Cas No. | 2410512-38-6 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.